Diasome’s technology platform is based on the use of its proprietary HDV technology to deliver a wide range of critically necessary hormones and drugs to the liver, where the body primarily stores glucose. Currently available forms of injected insulin, used by all Type 1 diabetes patients and a large percentage of people with Type 2 diabetes, are unable to function in the body in the same way as naturally produced insulin. Diasome’s HDV system is designed to improve the way in which insulin works in people with diabetes by enabling greater amounts of injected insulin to reach the liver’s glucose storing cells. This is critically important because the liver is the only organ in the body that can both store glucose (to prevent high blood sugar levels) and release glucose (to prevent low blood sugar levels). But, the liver must have insulin in order to activate mealtime glucose storage, and peripherally injected insulins struggle to reach the liver. Enabling the liver the release stored sugar is especially necessary at night, during exercise, and when not eating in order to prevent blood sugar levels from becoming dangerously low, a potentially dangerous condition called hypoglycemia.
Diasome’s pipeline includes multiple injected and oral formulations of liver targeted insulins for both Type 1 and Type 2 diabetic patients that are Phase 3 ready. The company is also developing a first-in-class oral compound for Type 2 diabetes patients based upon new research into normal glucose metabolism and a novel mechanism of action, along with a nanotechnology-based oral compound that may have a crucial impact in treating obesity.